Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of bosutinib in autosomal dominant polycystic kidney disease
2010-023017-65Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autosomal dominant polycystic kidney disease (ADPKD) comparing Bosutinib with Placebo (2 arms). Primary endpoint: Annualized rate of kidney enlargement. Started Jan 2011; status: completed.
02
Drugs
bosutinib
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2010-023017-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023017-65.